Remdesivir for the treatment of COVID 19: review of the pharmacological properties, safety and clinical effectiveness

References

• Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26:681–687.
   PubMed Web of Science ®Google Scholar
• Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19). JAMA. 2020;324:782.
   PubMed Web of Science ®Google Scholar
• World Health Organization [Internet]. Clinical management of COVID-19. interim guidance. 2020.
   Google Scholar
• Eastman RT, Roth JS, Brimacombe KR, et al. Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Central Sci. 2020;6(5):672-683.
   Web of Science ®Google Scholar
• Lo MK, Jordan R, Arvey A, et al. GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep 7, 43395 (2017)
   Google Scholar
• Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Trans Med. 2017;9(396):eaal3653.
   Web of Science ®Google Scholar
• Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019 Sep;169:104541.
   Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269-271.
   PubMed Web of Science ®Google Scholar
• LEXICOMP [Internet]. Wolters kluwer . 2020. [cited 2021 Jan 6]. Availale from: https://online.lexi.com/lco/action/doc/retrieve/docid/patch_f/6925182?cesid=2E1Mu9wRayY&searchUrl=%2Flco%2Faction%2Fsearch%3Fq%3Dremdesivir%26t%3Dname%26va%3Dremdesivir#pha
   Google Scholar
• Humeniuk R, Mathias A, Cao H, et al. Safety, tolerability, and pharmacokinetics of remdesivir, an antiviral for treatment of COVID‐19, in healthy subjects. Clin Transl Sci. 2020;cts:12840.
   Google Scholar
• Hu W, Chang L, Yang Y, et al. Pharmacokinetics and tissue distribution of remdesivir and its metabolites nucleotide monophosphate, nucleotide triphosphate, and nucleoside in mice. Acta Pharmacol Sin. 2021;42(7):1195-1200.
   Web of Science ®Google Scholar
• Siegel D, Hui HC, Doerffler E, et al. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1- f][triazin-4-amino] adenine C -nucleoside (GS-5734) for the treatment of ebola and emerging viruses. J Med Chem. 2017;60. DOI:https://doi.org/10.1021/acs.jmedchem.6b01594
   Google Scholar
• Jacobs M, Rodger A, Bell DJ, et al. Late ebola virus relapse causing meningoencephalitis: a case report. Lancet. 2016;388(10043):498–503.
   Web of Science ®Google Scholar
• Mulangu S, Dodd LE, Davey RT, et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019;381(24):2293–2303.
   PubMed Web of Science ®Google Scholar
• COVID 19 Investigation team. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med. 2020;26(6):861–868.
   Web of Science ®Google Scholar
• Holshue ML, DeBolt C, Lindquist S, et al. First case of 2019 Novel coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-936.
   Web of Science ®Google Scholar
• Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020;382(24):2327–2336.
   Web of Science ®Google Scholar
• Antinori S, Cossu MV, Ridolfo AL, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: clinical outcome and differences in post-treatment hospitalisation status. Pharmacol Res. 2020;158:104899.
   Web of Science ®Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569–1578.
   Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 — final report. N Engl J Med. 2020;383(19):1813–1826.
   Web of Science ®Google Scholar
• Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe covid-19. N Engl J Med. 2020;383(19):1827–1837.
   Web of Science ®Google Scholar
• Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19. JAMA. 2020;324(11):1048.
   PubMed Web of Science ®Google Scholar
• WHO Solidarity Trial Consortium. „Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results.“ New England journal of medicine. 2020;384(6):497-511.
   Google Scholar
• Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med. 2021;384(9):795-807.
   Web of Science ®Google Scholar
• Piscoya A, Ng-Sueng LF, Parra del Riego A, et al. Efficacy and harms of remdesivir for the treatment of COVID-19: a systematic review and meta-analysis. Bhatt GC, editor. PLOS ONE. 2020;15(12):e0243705.
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Briasoulis A, Takagi H, et al. Effect of remdesivir on patients with COVID-19: a network meta-analysis of randomized control trials. Virus Res. 2020;288:198137.
   PubMed Web of Science ®Google Scholar
• Wang M, Wu T, Zuo Z, et al. Evaluation of current medical approaches for COVID-19: a systematic review and meta-analysis. BMJ Support Palliat Care. 2021;11(1):45-52.
   Web of Science ®Google Scholar
• Elsawah HK, Elsokary MA, Abdallah MS, et al. Efficacy and safety of remdesivir in hospitalized Covid‐19 patients: systematic review and meta‐analysis including network meta‐analysis. Rev Med Virol. 2021 Jul;31(4):e2187.
   Google Scholar
• Jiang Y, Chen D, Cai D, et al. Effectiveness of remdesivir for the treatment of hospitalized COVID‐19 persons: a network meta‐analysis. J Med Virol. 2021;93:1171–1174.
   PubMed Web of Science ®Google Scholar
• Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review and network meta-analysis. BMJ. 2020;370:m2980.
   Google Scholar
• Shrestha DB, Budhathoki P, Syed N-I-H, et al. Remdesivir: a potential game-changer or just a myth? A systematic review and meta-analysis. Life Sci. 2021;264:118663.
   PubMed Web of Science ®Google Scholar
• Nasir M, Talha KA, Islam T, et al. Use of remdesivir in the management of COVID-19: a systematic review on current evidences. Mymensingh Med J. 2020;29:481–487.
   PubMedGoogle Scholar
• Nasir M, Perveen RA, Murshed M, et al. Survival and biomarkers of COVID-19 patients treated with remdesivir and favipiravir in ICU during the peak of pandemic: a Single Center Study in Bangladesh. J Pharm Res Int. 2021:14–22. DOI:https://doi.org/10.9734/jpri/2020/v32i4531088
   Google Scholar
• NIH. Coronavirus disease 2019 (COVID-19) treatment guidelines. 2020;2019:130. Disponible en: https://covid19treatmentguidelines.nih.gov/.Nih.
   Google Scholar
• World Health Organization (WHO). Therapeutics and COVID-19. Living guideline. 2020 Nov 20 [cited 2021 January 6]. Available from: https://apps.who.int/iris/handle/10665/336729.
   Google Scholar
• Bhimraj A 1, Morgan RL 2, Shumaker AH 3, et al. Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19. Clin Infect Dis. 2020 Apr 27:ciaa478.
   Google Scholar
• U.S. Department of health and human services, National Institutes of Health, National Institute of Allergy and Infectious Diseases D of AIDSD of A (DAIDS). Table for grading the severity of adult and pediatric adverse events, Corrected Version 2.1. [July 2017]. 2017 [cited 2021 Jun 30]. Available from: https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf
   Google Scholar
• Bai C, Chotirmall SH, Rello J, et al. Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated international task force (29 July 2020). Eur Respir Rev. 2020;29(157):200287.
   PubMed Web of Science ®Google Scholar
• Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter initial guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J Pediatr Infect Dis Soc. 2020;9(6):701–715.
   Web of Science ®Google Scholar
• Bertolini A, Peppel IP, Bodewes FAJA, et al. Abnormal Liver function tests in patients with COVID-19: relevance and potential pathogenesis. Hepatology. 2020;72(5):1864–1872.
   PubMed Web of Science ®Google Scholar
• FDA Adverse Event Reporting System (FAERS) public dashboard. U.S. Food & Drug administration. 2020 [cited 2021 January 6]. Available from: https://www.fda.gov/drugs/questions-and-answers-fdas-adverse-event-reporting-system-faers/fda-adverse-event-reporting-system-faers-public-dashboard
   Google Scholar
• Bialek S, Gierke R, Hughes M, et al. Coronavirus disease 2019 in children — United States, February 12–April 2, 2020. MMWR. Morbidity and Mortality Weekly Report. 2020;69(14):422–426.
   PubMed Web of Science ®Google Scholar
• Chao JY, Derespina KR, Herold BC, et al. Clinical characteristics and outcomes of hospitalized and critically ill children and adolescents with coronavirus disease 2019 at a Tertiary Care Medical Center in New York City. J Pediatr. 2020;223:14–19.e2.
   PubMed Web of Science ®Google Scholar
• Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children in China. Pediatrics. 2020;145(6):e20200702.
   PubMed Web of Science ®Google Scholar
• Götzinger F, Santiago-García B, Noguera-Julián A, et al. COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. Lancet Child Adolesc Health. 2020;4(9):653–661.
   PubMedGoogle Scholar
• Kaushik S, Aydin SI, Derespina KR, et al. Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2 infection (MIS-C): a Multi-institutional Study from New York City. J Pediatr. 2020;224:24–29.
   PubMed Web of Science ®Google Scholar
• Louchet M, Sibiude J, Peytavin G, et al. Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019. Am J Obstet Gynecol. 2020;2(3):100159.
   Web of Science ®Google Scholar
• Igbinosa I, Miller S, Bianco K, et al. Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019. Am J Obstet Gynecol. 2020;223(5):768–770.
   PubMed Web of Science ®Google Scholar
• McCoy JA, Short WR, Srinivas SK, et al. Compassionate use of remdesivir for treatment of severe coronavirus disease 2019 in pregnant women at a United States academic center. Am J Obstet Gynecol. 2020;2(3):100164.
   Web of Science ®Google Scholar
• Maldarelli GA, Savage M, Mazur S, et al. Remdesivir treatment for severe COVID-19 in third-trimester pregnancy: case report and management discussion. Open Forum Infect Dis. 2020;7(9):ofaa345.
   Web of Science ®Google Scholar
• Naqvi M, Zakowski P, Glucksman L, et al. Tocilizumab and remdesivir in a pregnant patient with coronavirus disease 2019 (COVID-19). Obstet Gynecol. 2020;136(5):1025–1029.
   PubMed Web of Science ®Google Scholar
• Burwick RM, Yawetz S, Stephenson KE, et al. Compassionate use of remdesivir in pregnant women with severe coronavirus disease 2019. Clin Infect Dis. 2020 Oct 8:ciaa1466. DOI:https://doi.org/10.1093/cid/ciaa1466
   Google Scholar
• Sörgel F, Malin JJ, Hagmann H, et al. Pharmacokinetics of remdesivir in a COVID-19 patient with end-stage renal disease on intermittent haemodialysis. J Antimicrob Chemother. 2021 Feb 11;76(3):825-827. .
   Web of Science ®Google Scholar
• Davis MR, Pham CU, Cies JJ. Remdesivir and GS-441524 plasma concentrations in patients with end-stage renal disease on haemodialysis. J Antimicrob Chemother. 2021 Feb 11;76(3):822-825.
   Web of Science ®Google Scholar
• Aiswarya D, Arumugam V, Dineshkumar T, et al. Use Of Remdesivir In Patients With Covid-19 On Hemodialysis- A Study Of Safety And Tolerance. Kidney Int Rep. 2021 Mar;6(3):586-593.
   Web of Science ®Google Scholar
• (AASLD) TAA for the S of LD. Clinical insights for hepatology and liver transplant providers during the COVID-19 pandemic [Internet]. 2020 [cited 2021 Jun 30]. Available from: https://www.aasld.org/sites/default/files/2020-11/AASLD-COVID19-ExpertPanelConsensusStatement-November092020.pdf
   Google Scholar
• National Center for Biotechnology Information (2021). PubChem compound summary for CID 121304016, remdesivir. [Internet]. PubChem. [cited 2021 Jul 22].
   Google Scholar